US2006210991A1PendingUtilityA1

Interleukin-8 homologous polypeptides and therapeutic uses thereof

50
Individually held — no corporate assignee on recordPriority: Jun 25, 1998Filed: Mar 9, 2004Published: Sep 21, 2006
Est. expiryJun 25, 2018(expired)· nominal 20-yr term from priority
Inventors:Dan EatonDorothy FrenchJ. Christopher GrimaldiKenneth HillanMaria PisabarroKerstin SchmidtVictoria SmithDaniel TumasRichard VandlenColin WatanabeP. WilliamsWilliam Wood
G01N 33/564C07K 14/5421C12Q 2600/158C07K 14/705G01N 33/6863G01N 33/6869C12Q 2600/136G01N 33/6893C12Q 1/6883C07K 14/52C07K 14/47
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treatment and diagnosis of inflammatory diseases.

Claims

exact text as granted — not AI-modified
1 .- 32 . (canceled)  
     
     
         33 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    comparing the level of expression of a gene encoding PRO842 polypeptide in said test sample to the level of expression of said gene encoding PRO842 in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in said test sample indicates the presence of an immune related disease in said mammal from which said test sample of tissue cells were obtained.    
     
     
         34 . The method of  claim 33  wherein the immune related disease is an immune-mediated inflammatory disease.  
     
     
         35 . The method of  claim 33  wherein the immune related disease is a non-immune-mediated inflammatory disease.  
     
     
         36 . The method of  claim 33  wherein the immune related disease is an infectious disease.  
     
     
         37 . The method of  claim 33  wherein the immune related disease is an immunodeficiency disease.  
     
     
         38 . The method of  claim 33  wherein the immune related disease is a neoplasia.  
     
     
         39 . The method of  claim 33  wherein said immune related disease is selected from the group consisting of: systemic lupus erythematosis, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory myopathies, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central nervous systems, demyelinating diseases of the peripheral nervous system, hepatobiliary diseases, inflammatory bowel disease, gluten-sensitive enteropathy, and Whipple's disease, autoimmune or immune-mediated skin diseases, psoriasis, allergic diseases, immunologic diseases of the ovaries, immunologic diseases of the lung, transplantation associated diseases, viral diseases, AIDS, herpes, bacterial infections, fungal infections, protozoal infections, parasitic infections, infectious diseases, immunodeficiency disease and neoplasia.  
     
     
         40 . The method  claim 39  wherein said idiopathic inflammatory myopathy is selected from the group consisting of dermatomyositis and polymyositis.  
     
     
         41 . The method of  claim 39  wherein said autoimmune hemolytic anemia is selected from the group consisting of immune pancytopenia and paroxysmal nocturnal hemoglobinuria.  
     
     
         42 . The method of  claim 39  wherein said autoimmune thrombocytopenia is selected from the group consisting of idiopathic thrombocytopenic purpura and immune-mediated thrombocytopenia.  
     
     
         43 . The method of  claim 39  wherein said thyroiditis is selected from the group consisting of Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis and atrophic thyroiditis.  
     
     
         44 . The method of  claim 39  wherein said immune-mediated renal disease is selected from the group consisting of glomerulonephritis and tubulointerstitial nephritis.  
     
     
         45 . The method of  claim 39  wherein said demyelinating disease is selected from the group consisting of multiple sclerosis, idiopathic demyelinating polyneuropathy, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy.  
     
     
         46 . The method of  claim 39  wherein said hepatobiliary disease is selected from the group consisting of hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis.  
     
     
         47 . The method of  claim 39  wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.  
     
     
         48 . The method of  claim 39  wherein said autoimmune or immune-mediated skin disease is selected from the group consisting of bullous skin diseases, erythema multiforme and contact dermatitis.  
     
     
         49 . The method of  claim 39  wherein said allergic disease is selected from the group consisting of asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria.  
     
     
         50 . The method of  claim 39  wherein said allergic disease is selected from the group consisting of eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis.  
     
     
         51 . The method of  claim 39  wherein said transplantation associated disease is selected from the group consisting of graft rejection and graft-versus-host-disease.  
     
     
         52 . The method of  claim 39  wherein said immune related disease is lupus erythematosis.  
     
     
         53 . The method of  claim 39  wherein said immune related disease is rheumatoid arthritis.  
     
     
         54 . The method of  claim 39  where in said neoplasia is a breast neoplasia.  
     
     
         55 . The method of  claim 39  wherein said neoplasia is a lung neoplasia.  
     
     
         56 . The method of  claim 39  wherein said neoplasia is a colon neoplasia.  
     
     
         57 . A method of diagnosing an immune-related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule comprising a nucleotide sequence that encodes a PRO842 polypeptide of SEQ ID NO:2 in said test sample of tissue cells.    
     
     
         58 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity to a nucleic acid molecule encoding a PRO842 polypeptide of SEQ ID NO:2.    
     
     
         59 . The method of  claim 58  wherein said PRO842 polypeptide of SEQ ID NO:2 has an amino acid sequence lacking a signal peptide.  
     
     
         60 . The method of  claim 58  wherein said PRO842 polypeptide of SEQ ID NO:2 comprises an extracellular domain of a transmembrane protein.  
     
     
         61 . The method of  claim 58  wherein said PRO842 polypeptide of SEQ ID NO:2 comprises an extracellular domain of a transmembrane protein and a signal peptide.  
     
     
         62 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule in said test sample of tissue cells comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity to a nucleic acid molecule comprising the coding sequence of a PRO842 polypeptide of SEQ ID NO:2.    
     
     
         63 . The method of  claim 62  wherein said PRO842 polypeptide of SEQ ID NO:2 has an amino acid sequence lacking a signal peptide.  
     
     
         64 . The method of  claim 62  wherein said PRO842 polypeptide of SEQ ID NO:2 comprises an extracellular domain of a transmembrane protein.  
     
     
         65 . The method of  claim 62  wherein said PRO842 polypeptide of SEQ ID NO:2 comprises an extracellular domain of a transmembrane protein and a signal peptide.  
     
     
         66 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule in said test sample of tissue cells comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity to a nucleic acid molecule that encodes a polypeptide encoded by a human protein cDNA of SEQ ID NO:1.    
     
     
         67 . A method of  claim 66  wherein the nucleic acid sequence is the complement of the cDNA molecule of SEQ ID NO:1.  
     
     
         68 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule in said test sample of tissue cells comprising a nucleotide sequence encoding a PRO842 polypeptide of SEQ ID NO:2 wherein said polypeptide is transmembrane-domain deleted.    
     
     
         69 . The method of  claim 68  comprising the complement of said nucleotide sequence.  
     
     
         70 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule in said test sample of tissue cells comprising a nucleotide sequence encoding a PRO842 polypeptide of SEQ ID NO:2 wherein said polypeptide is transmembrane domain-inactivated.    
     
     
         71 . The method of  claim 70  comprising the complement of said nucleic acid sequence.  
     
     
         72 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a nucleic acid molecule in said test sample of tissue cells comprising a nucleotide sequence encoding the polypeptide encoded by the human protein cDNA ATCC deposit number 203004.    
     
     
         73 . The method of  claim 72  comprising the complement of said nucleotide sequence.  
     
     
         74 . A method of determining the presence of a nucleic acid sequence encoding a PRO842 polypeptide of SEQ ID NO:2 in a sample comprising: 
 providing a sample    contacting such sample with a probe, wherein said probe has a sequence identical to at least about 20 contiguous nucleotide bases of SEQ ID NO:1 or a sequence complementary to SEQ ID NO:1,    detecting the presence of said nucleotide sequence.    
     
     
         75 . The method of  claim 74  where in said probe is detectably labeled using radiolabeled ATP, biotinylation or an enzyme.  
     
     
         76 . The method of  claim 74  wherein said probe has at least about 20 to at least about 80 nucleotides in length.  
     
     
         77 . The method of  claim 74  wherein said probe contains at least about 20 contiguous nucleotide bases of the cDNA of SEQ ID NO:1.  
     
     
         78 . The method of  claim 74  wherein said hybridization probe contains at least about 40 contiguous nucleotide bases of the cDNA of SEQ ID NO:1.  
     
     
         79 . The method of  claim 74  wherein said probe contains at least about 80 contiguous nucleotide bases of the cDNA of SEQ ID NO:1.

Join the waitlist — get patent alerts

Track US2006210991A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.